Melphalan
Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.
Clinical data | |
---|---|
Trade names | Alkeran, Evomela, Phelinun, others |
Other names | (2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682220 |
License data | |
Routes of administration | By mouth, intravenous, intra-arterial |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 25–89% (By mouth) |
Metabolism | Hydrolysis to inactive metabolites |
Elimination half-life | 1.5 ± 0.8 hours |
Excretion | Kidney (IV: 5.8–21.3%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.207 |
Chemical and physical data | |
Formula | C13H18Cl2N2O2 |
Molar mass | 305.20 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include nausea and bone marrow suppression. Other severe side effects may include anaphylaxis and the development of other cancers. Use during pregnancy may result in harm to the fetus. Melphalan belongs to the class of nitrogen mustard alkylating agents. It works by interfering with the creation of DNA and RNA.
Melphalan was approved for medical use in the United States in 1964. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.